BioCentury
ARTICLE | Clinical News

Madrigal completes enrollment in Phase II of MGL-3196 for HeFH

September 22, 2017 7:54 PM UTC

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said it has enrolled 113 patients in a Phase II trial of MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH), exceeding its target enrollment of 105. The company said it would continue enrollment "for the next several days."

The double-blind, placebo-controlled, European trial is evaluating MGL-3196 for 12 weeks in combination with patients' current drug regimens, including high-dose statins and/or the cholesterol absorption inhibitor Zetia ezetimibe from Merck & Co. Inc. (NYSE:MRK). The primary endpoint is the mean percent change from baseline in LDL-C. Secondary endpoints include mean percent change from baseline in non-HDL-C, triglycerides, lipoprotein(a) (LPA), apolipoprotein B (APOB), total cholesterol/HDL-C ratio, apolipoprotein A-1 (APOA1; apo(a))/APOB ratio and lipoprotein particle assessment and safety...